Buy Geftinat (Geftinib 250mg) 30 Tablet | Online Price of Anticancer medicine Geftinat from India|
• Brand name: Geftinat
• Active ingredients: Gefitinib 250 mg
• Manufacturer: NATCO
• Country of origin: India
• Packing: 250mg (30 tablets)
• Pharm group: Antineoplastic means
Geftinat description of the drug
Geftinat is the drug use for curing cancer, you can Buy Geftinat 250mg 30 Tablet from India and you can check Online Price of Geftinat Anticancer medicine from India, visit our website – http://medimpexindia.com/ .
Gefitinib is a selective inhibitor of the tyrosine kinase receptors epidermal growth factor, the expression of which is observed in many solid tumors, inhibits the growth of various lines of human tumor cells, metastasis and angiogenesis and accelerates apoptosis of tumor cells enhances the antitumor activity of chemotherapeutic drugs, radiation, and hormone therapy.
1 tablet contains 250 mg of gefitinib;
Excipients: lactose, microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, polyvinylpyrrolidone K-30, magnesium stearate, E-5, polyethylene glycol 300, titanium dioxide, iron oxide red, iron oxide yellow.
Antineoplastics funds (inhibitor protein-containing). ATC code L01XX31.
Pharmacodynamics. Gefitinib is a selective inhibitor of the tyrosine kinase receptors epidermal growth factor, the expression of which is observed in many solid tumors, inhibits the growth of various lines of human tumor cells, metastasis and angiogenesis and accelerates apoptosis of tumor cells enhances the antitumor activity of chemotherapeutic drugs, radiation, and hormone therapy.
Once inside absorbed relatively slowly. Bioavailability is 59%. Food intake does not affect bioavailability. When pH of gastric juice above 5, the bioavailability of gefitinib reduced by 47%. A steady-state concentration in plasma (CSS) is achieved after intake of 7-10 doses. Regular use of the drug 1 time per day leads to an increase in the concentration of 2-8 times in comparison with the single administration. The time to reach maximum concentration in plasma (TCmax), 3-7 p.m. The volume of distribution of gefitinib in achieving Css – 1400 l indicating the extensive distribution of the drug in the tissues. Connection with plasma proteins (albumin and alpha 1-glycoprotein) is approximately 90%. Undergoes oxidative metabolism by the enzyme CYP3A4 of cytochrome P450. In vitro slightly inhibits the enzyme CYP2D6. The metabolism of gefitinib happens 3 ways: the metabolism of N – propeller-driven group, demethylation metaxylene group on quinazoline part and oxidative dephosphorylation galogenirovannami phenyl groups. The main metabolite, which is determined in the blood plasma, the Pro – demethylation, which has 14 times less pharmacological activity compared with gefitinib relative to the cell growth stimulated by an epidermal growth factor, which suggests that a significant impact on the clinical activity of gefitinib unlikely. Total clearance of gefitinib – about 500 ml/min. the elimination half-life (T1 / 2) – 41 hours Excreted mainly in feces; the renal output of less than 4% of the administered dose. When moderate hepatic insufficiency, the pharmacokinetics does not change significantly. In severe hepatic impairment due to liver metastases with similar CSS such as normal liver function.
Locally common or metastatic nemelcockletocny lung cancer refractory to chemotherapy regimes containing platinum derivatives and docetaxel.
Method of application and doses
Inside, 250 mg 1 time per day regardless of the meal. Tablet ib 250 can be dissolved in 100 ml of drinking (non-carbonated) water. Other liquids can be used. For proper dissolution you need to drop the pill into the water, stretching, stirring until dissolved (about 10 min) And immediately drink the resulting solution. Pour another 1e Naso-gastral probe.
Most often (20%) are observed such adverse reactions when taking ib 250: diarrhea, skin (including acne) rash, itching, dry skin. Of course, occur within the first month of treatment and usually is reversible. 8% of patients had serious adverse reactions (3 to 4 degrees of severity according to common toxicity criteria), but only 1% of patients therapy was discontinued due to adverse reactions.
Very often (more 10%); often (more than 1 and less than 10%); not often (more than 0.1 and less than 1%); rare (more than 0.01 and less than 0.1%); very rare (less than 0.01%).
On the part of the blood: often – hematuria, epistaxis; not often, hypercoagulation and/or increased frequency of bleeding in patients receiving warfarin.
From the digestive system: very often – diarrhea (in some cases severe), nausea, often vomiting, anorexia, stomatitis, dehydration, the asymptomatic increased activity of “liver” transaminases; rarely – pancreatitis.
On the part of the organ of vision: often – conjunctivitis, blepharitis; rare – the reverse erosion of the cornea, impaired the growth of eyelashes.
The respiratory system: rarely – interstitial pneumonia (3 to 4 toxicity, including death).
With the skin: very often – rash (pustular), pruritus, dry skin on the background of erythema; often, nail changes, alopecia very rarely – toxic epidermal necrolysis and erythema multiforme exudative.
very rarely – angioneurotic edema, urticaria.
Other: often – asthenia.
Hypersensitivity, pregnancy, lactation, childhood, and adolescence (safety and efficacy not established).
Symptoms: increased frequency and severity of side effects, mainly diarrhea, and skin rashes. Treatment is symptomatic. The antidote is unknown.
Be wary appoint ib 250 idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, post-radiation pneumonia, pneumonitis the drug (marked by elevated levels of mortality from these diseases during the treatment of prepared) the increased activity of “liver” transaminases.
On the background of treatment with 250 Geminatum been cases of interstitial lung disease (including fatalities). With an increase in symptoms such as shortness of breath, cough, fever, the use of the drug should be discontinued immediately and the survey. If the patient confirmed the presence of interstitial lung disease stop taking the drug and prescribe the appropriate treatment.
On the background of treatment showed asymptomatic increases in liver transaminases, and in this connection, it is necessary to periodically monitor liver function. In marked elevation of transaminases use geftinib 250 should be discontinued.
Patients taking warfarin should regularly monitor the prothrombin time.
With the advent of any symptoms of vision or if you develop severe or prolonged diarrhea, nausea, vomiting or anorexia, the patient should immediately consult a doctor.
If the patients have hard docked diarrhea during treatment or adverse reactions with the skin, possible short-term treatment interruption (up to 14 days), followed by resumption of treatment with Geminatum 250 at a dose of 1 tablet per day.
When using ib 250 in combination with radiotherapy as first-line therapy in children with brainstem glioma or incompletely remote with glioma of supratentorial localization were reported 4 cases (one fatal) hemorrhage in the brain. Another case of cerebral hemorrhage was noted in a child with Ependymoma in monotherapy gefitinib. In patients with small cell lung cancer in the treatment ib 250mg similar side effects were recorded.
Women of childbearing age and men during treatment and for at least 3 months after it should use reliable methods of contraception.
During the reception, Pettinato 250 care must be taken when driving and when working with equipment.
Interaction with other drugs
ib 250 enhances the neutropenia caused by the use of Vinorelbine. Rifampin (a potent inducer of CYP3A4) reduces the AUC of gefitinib by 83%. Itraconazole (an inhibitor of the enzyme CYP3A4) increases the AUC (area under the curve of concentration/hour) of gefitinib 80%, which can be clinically significant. The drug substantially and permanently increases the pH of gastric contents, reduce gefitinib AUC by 47%. Medicines – inducers of CYP3A4 (phenytoin, carbamazepine, barbiturates, tincture of St. John’s wort) may increase metabolism and decrease the concentration of gefitinib in the blood plasma, which can lead to reduced efficiency. Simultaneous administration of metoprolol (a CYP2D6 substrate) resulted in a slight increase (by 35%) the concentration of metoprolol, which is not clinically significant.
Store in a dry, protected from the light place at the temperature not exceeding 250 C. the Drug should be stored out of reach of children.
Shelf life – 2 years.
30 tablets in a plastic container, 1 plastic container in a cardboard box.
Manufacturer- NATCO PHARMA LIMITED.